EYEPOINT PHARMAC. DL-01
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases com… Read more
EYEPOINT PHARMAC. DL-01 (PV3B) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, EYEPOINT PHARMAC. DL-01 (PV3B) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
EYEPOINT PHARMAC. DL-01 - Net Assets Trend (None–None)
This chart illustrates how EYEPOINT PHARMAC. DL-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for EYEPOINT PHARMAC. DL-01 (None–None)
The table below shows the annual net assets of EYEPOINT PHARMAC. DL-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to EYEPOINT PHARMAC. DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
EYEPOINT PHARMAC. DL-01 Competitors by Market Cap
The table below lists competitors of EYEPOINT PHARMAC. DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OVS S.p.A.
LSE:0R5R
|
$729.84 Million |
|
Matthews International Corporation
NASDAQ:MATW
|
$730.27 Million |
|
Shanghai Medicilon Inc
SHG:688202
|
$730.34 Million |
|
Heritage Commerce Corp
NASDAQ:HTBK
|
$730.72 Million |
|
Jiangsu Shuangxing Color Plastic New Materials Co Ltd
SHE:002585
|
$729.18 Million |
|
Janus International Group Inc
NYSE:JBI
|
$728.65 Million |
|
PETERSHILL PARTNERS -01
F:9X7
|
$728.62 Million |
|
Shenzhen Farben Information Technology Co.Ltd.
SHE:300925
|
$728.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EYEPOINT PHARMAC. DL-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares EYEPOINT PHARMAC. DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently EYEPOINT PHARMAC. DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares EYEPOINT PHARMAC. DL-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EYEPOINT PHARMAC. DL-01 (PV3B) | €- | N/A | N/A | $729.65 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |